- Research article
- Open Access
Prevalence and determinants of adherence to HAART amongst PLHIV in a tertiary health facility in south-south Nigeria
BMC Infectious Diseases volume 13, Article number: 401 (2013)
Adherence to Highly active antiretroviral therapy (HAART) is a major predictor of the success of HIV/AIDS treatment. Good adherence to HAART is necessary to achieve the best virologic response, lower the risk of drug resistance and reduce morbidity and mortality. This study therefore aimed to determine the prevalence and determinants of adherence to HAART amongst PLHIV accessing treatment in a tertiary location in Cross River State, Nigeria.
A cross-sectional study was conducted among patients on HAART attending the Presidential Emergency plan for AIDS relief (PEPFAR) clinic of the University of Calabar Teaching Hospital between October–December 2011. A total of 411 PLHIV visiting the study site during the study period were interviewed. PLHIV who met the inclusion criteria were consecutively recruited into the study till the desired sample size was attained. Information was obtained from participants using a semi-structured, pretested, interviewer administered questionnaire. Adherence was measured via patients self report and were termed adherent if they took at least 95% of prescribed medication in the previous week prior to the study. Data were summarized using proportions, and χ 2 test was used to explore associations between categorical variables. Predictors of adherence to HAART were determined by binary logistic regression. Level of significance was set at p < 0.05.
The mean age of PLHIV who accessed treatment was 35.7 ± 9.32 years. Females constituted 68.6% of all participants. The self reported adherence rate based on a one week recall prior to the study was 59.9%. The major reasons cited by respondents for skipping doses were operating a busy schedule, simply forgot medications, felt depressed, and travelling out of town. On logistic regression analysis, perceived improved health status [OR 3.11; CI: 1.58-6.11], reduced pill load [OR 1.25; 95% CI: 0.46-2.72] and non-use of herbal remedies [OR 1.83; 95% CI: 1.22-2.72] were the major predictors for adherence to HAART. However, payment for ART services significantly decreased the likelihood of adherence to HAART. [OR 0.46; 95% CI: 0.25-0.87.].
The adherence rate reported in this study was quite low. Appropriate adherence enhancing intervention strategies targeted at reducing pill load and ensuring an uninterrupted access to free services regimen is strongly recommended.
The Human immunodeficiency virus (HIV) pandemic continues to spread in the population making HIV infection one of the most important public health crises in the world . Globally, about 33.3 million persons were estimated to be infected with HIV/AIDS in 2010, of these, 22.5 million (68%) are in sub Saharan Africa and about 3 million alone in Nigeria. This makes it the country with the second highest burden of HIV and AIDS in the world after South Africa . The current prevalence rate of HIV in Nigeria as at 2010 based on the sentinel surveillance is 4.1%. Cross River State were the study was conducted currently has the 9th highest prevalence (7.1%) in the country as at 2010 and is found in the South-south geopolitical zone of Nigeria .
In the absence of a cure, antiretroviral therapy (ART) has remained the only available option that offers the possibility of dramatically reducing HIV/AIDS-related morbidity and mortality, while improving the status of PLHIV. It has proved effective in reducing viral load, improving immune function,  and improving the quality of life of PLHIV [3, 4]. However, successful long-term treatment of HIV requires strict adherence to the Highly Active Antiretroviral Therapy (HAART) regimen [3, 5, 6]. This is especially important in countries such as Nigeria where PLHIV make up 10% of the global burden of HIV/AIDS  and about 1.5 million require treatment . Adherence level of at least 95% and above has been considered appropriate to achieve therapeutic success, [8–11] as this maintains optimal viral suppression as demonstrated by Paterson and colleagues [11–13]. Failure to observe sustained desired adherence threshold has been associated with dire consequences such as treatment failure, disease progression and emergence of drug resistant HIV/IADS strains [14, 15].
With the realization of the central role played by adherence in the success of HIV/AIDS treatment, several studies conducted in various parts of the world including reviews have reported non-adherence rates ranging from 50% to 80% in different contexts [9, 10, 16]. However, in reality adherence rates are often lower than 95%  and rates of adherence from previous studies conducted in Nigeria have ranged from as low as 44% being adherent  to more than 95% from different parts of Nigeria . Most of the previous reports were carried out with fewer PLHIV being on treatment restricted access to ARV drugs unavailability and payment for ARV medications were heavily subsidized.
With wide spread awareness of HIV/AIDS, expansion of treatment and prevention programs that have increased ART access to previously un-served and underserved populations in Nigeria coupled with provision of free ART services,  there is a need for implementation of continuous monitoring and evaluation mechanisms for adherence, This is of great importance especially because the key to the success of ART programmes and prevention of treatment failures is hinged on consistently high adherence levels. Scaling up of ARVs alone is definitely not the answer when adherence inconsistencies are not tackled. Therefore, the first step to solving this problem is to assess the determinants of adherence to HAART which may differ across geopolitical zones of the country with their unique characteristics of culture, religion, educational status and health seeking behaviours. The objectives of the present study were to determine the prevalence of adherence to HAART and identify factors associated with adherence.
The study was conducted at the President’s Emergency plan for AIDS Relief (PEPFAR) clinic now the Specialist treatment clinic of the University of Calabar Teaching Hospital. The Hospital was selected as a centre for the implementation of the President’s Emergency plan for AIDS Relief (PEPFAR) by the United States Agency for International Development (USAID) in June 2005. It has since been responsible for the provision of care and support services for PLHIV as well as one of the major centres where PLHIV both in Cross River and other neighbouring states receive anti retroviral therapy. The patient population is about 4,000, of which more than 2,000 are on treatment. The clinic is run under three units. The paediatric adult and the Prevention of Maternal to Child transmission (PMTCT) clinics.
The study population comprised of 411 HIV positive clients who were enrolled and had commenced HAART in UCTH from October 2011- December 2011. They were made of 129 males and 282 females. Participants were consecutively recruited over the study period till the desired sample size was attained. All PLHIV on HAART were eligible to participate except those that satisfied the exclusion criteria. These criteria included PLHIV below 18 years of age, who were attending the clinic but had not commenced HAART, terminally ill patients and pregnant women. The inclusion criteria adopted for the study included consenting out patients diagnosed and confirmed to be HIV positive, at least 18 years of age and had been on HAART for 3 months.
A cross-sectional analytical study aimed at documenting the level of adherence among PLHIV on HAART was conducted between October 2011- December 2011.
Data collection instrument
This consisted of an interviewer administered semi-structured questionnaire which was divided into sections to collect relevant information on socio-demographic data, medical profile including treatment experiences at health facility of respondents. Adherence to HAART in the previous seven days of the interview was measured by self-report. The questions were adopted from The Brief Medication Questionnaire self-report tool for screening adherence and barriers to adherence . The degree of adherence from patient self-reporting was estimated using the following formula: 
Then, the percentage of adherence to the antiretroviral was estimated by the average of adherence to the drugs. For the purpose of this study a score of 95% and above represented good adherence and less than 95% was rated as having poor/suboptimal adherence.
Data were analyzed using SPSS for windows version 19.0. Descriptive and inferential statistical tests were employed. These included bivariate (chi-square) and multivariate (logistic regression) analysis to determine correlates or predictors of adherence. Descriptive statistics (frequencies, proportions, means and standard deviation to summarize variables while Inferential statistics (chi square Test) was used to test the significance of association between categorical variables and level of significance was set at 5%. Logistic regression analysis was used to identify the predictors of adherence to HAART in the study population. Variables entered into the logistic model were those which had earlier been significantly associated on bivariate analysis at 10% significance derived. Predictors were determined at 5% significance.
Ethical clearance and consent
The ethical Committee of the University of Calabar Teaching Hospital reviewed and approved the study procedures and data collection instruments.
Four hundred and eleven eligible respondents receiving HAART at the PEPFAR clinic UCTH were studied. The mean age of respondents was 35.7 ± 9.3 years. The largest proportion of the PLHIV 171 (41.6%) were in the age group 25-34 years, followed by 136 (33.1%) in the 35 to 44 age group. The majority of those interviewed were female; 68.6% and currently married 51.8%. More than a third 39.7% had attained at least secondary education and 38.4% were of the skilled non manual occupational group. Also majority 85.9% resided within the state and 67.4% earned less than the minimum wage in Nigeria (<N19,000) monthly which is equivalent to $118.75. Almost all (99.8%) respondents interviewed were Christians (Table 1). The Medical profile of respondents interviewed (Table 2) revealed that more, 183 (44.5%) had been on HAART for more than 24 months. The median duration on HAART was 24 months (range 3–192 months). More than half of the study population 226 (55%) had encountered side effects since the commencement of HAART and majority 273 (66.4%) were not using any form of herbal treatment alongside their antiretroviral medications. Furthermore, a little over two-thirds of the respondents 282 (68.6%) were on at least 2 pills per day and a vast majority 386 (93.9%) perceived their health status as improved since their commencement on HAART. A few respondents 49 (11.9%) of the study population reported paying for services at the treatment site.
Prevalence of adherence to HAART in the study population showed that more than half (59.9%) of the respondents’ attained 95% adherence to prescribed HAART regimen. The main reasons cited for missing or skipping doses among respondents who missed their medications included being busy (43.8%), simply forgetting (31.1%), depression (20%), frequent travelling (14.8%) and inconvenient timing for medications schedule (12.7%). This is represented in Figure 1.
Factors associated with adherence on bivariate analysis (Tables 3 and 4) were; Being resident outside Cross river state, 42 (72.4%) was significantly more likely to adhere to HAART compared with 204 (57.8%) being resident within the state (p < 0.05). Similarly other significant correlates of adherence included obtaining free ART services, perceived health status as excellent/good and paid more than N1000 on transportation to the health care facility (p < 0.05) (Table 4). The predictors of adherence to HAART amongst PLHIV accessing treatment in PEPFAR clinic UCTH were non use of herbal remedies, obtaining free ART services, perceived improvement in health status, and reduced pill load. Participants not using herbal remedies were more likely to adhere to their prescribed doses compared with those using herbal remedies. Similarly obtaining free ART services, taking not more than two pills per day, and a perceived improvement in health following the commencement of HAART than those who paid for ART services, took more than 2 pills per day, and who reported their perceived health status as not improved. This is presented in Table 5.
The present study aimed to contribute towards addressing gap in knowledge regarding the prevalence and factors associated with treatment adherence among a representative sample of PLHIV accessing treatment site in Cross River State Nigeria.
The self reported adherence reported in the present study was 59.9%. This finding was comparable with other studies done in Nigeria and other African setting, [21–23] but slightly higher than earlier reports by Ilyasu and colleagues in Kano (Northern Nigeria),  Nwauche and colleagues (Southern Nigeria) and a study done in Kenya, who reported adherence levels of 54.5%. 49.2%and 43.2% respectively. However adherence level reported in this study was lower than seen in other studies [22, 24–26]. Our current findings showed that about two fifths of patients interviewed were non adherent both in terms of dose adherence and timing. Emphasis should therefore be placed on adherence to HAART especially during counselling sessions as this is required for optimal clinical response and complete viral suppression.
The major reasons cited by participants for missing doses included; operating a busy schedule and simply forgetting medications. These two reasons though related to one another have been cited by several studies as the main risk factors for suboptimal adherence [21, 23, 27–29]. Another important reason given by respondents for skipping or missing medications which is note worthy was feeling depressed. Approximately a fifth of the study population indicated feeling depressed as a reason for poor adherence to medications. This was similar to findings conducted in USA in 2010 where patients with symptoms of depression had higher rates of suboptimal adherence . Issues bothering around stigma and discrimination, personality traits, fear of being discovered, lack of social support, and poorer health outcomes may contribute strongly to emotional non-adjustment to HIV/AIDS, depression and loss of interest in ones treatment. This would ultimately result in poor adherence to medications amongst PLHIV.
Most socio-demographic characteristics such as age, sex, marital status, educational attainment did not significantly affect adherence levels amongst our study population. This corroborates the findings of some authors [17, 28, 31, 32] but refutes the findings of others were certain socio-demographic variables were associated with being adherent to HAART [24, 33].
Medication adherence was found to be significantly associated with non use of Traditional herbal medicines. The effect of the use of herbal remedies in addition to HAART was noted in this study. Non herbal use was demonstrated as a significant predictor of adherence in this study. This finding is in agreement with a study conducted in Ilorin, (south western Nigeria) were the use of herbal medicines was a major risk factor for non adherence  and a study done in South Africa by Peltzer et al. which demonstrated non use of herbal remedies as a major facilitator of adherence . The reason respondents may consider using herbal remedies could be attributable to the fact that some patients may gradually be losing faith in their anti-retrovirals which most are aware does not provide a cure and are opting for herbal remedies. Secondly, the proliferation of alternative healers and a claim on the media by traditional medicine practitioners of an instant cure for HIV infection may cause some to abandon their treatment.
Pill burden also significantly affected adherence in the present study. Respondents on more than two pills per day were less likely to adhere to their treatment compared to those on at least two pills per day. This finding was also identified as a significant predictor of adherence in a study done by Falang and colleagues in Jos  and Sow et al. in Senegal  where pill burden was reported to have a strong impact on adherence. Similarly, in India Cauldbeck et al. demonstrated that patients who attained 100% adherence took fewer pills . This could be attributable to the fact that these patients probably because of their busy schedules may have been unable to incorporate their drugs schedule into their daily schedule or may be developing pill fatigue. Reducing pill load as well as dosing schedules to once or twice daily has been found to be associated with better adherence .
Self reported improved health status was significantly associated with adherence amongst our study population. The odds of adherence among those who rated their health status as improved was three times compared to those who perceived their health as not improved. This study was in agreement with another study  where staying healthy was a key motivator of adherence to treatment. In contrast to our findings, Olowookere and colleagues in south western Nigeria reported that feeling good/healthy, were risk factors for non-adherence. They further reported that most patients tend to abandon treatment once there was an improvement in their health [21, 23].
Obtaining free treatment at ART clinics was a significant predictor of adherence to treatment. Respondents who didn’t pay for obtaining ART services were two times better adherers compared to those who paid for services. This was in keeping with studies done in the south western part of Nigeria,  and another study done in Botswana when cost were removed as a barrier, adherence was predicted to increase from 54% to 74% . Financial constraints among respondents were a major deterrent to adherence as observed in this study. Although drugs were given free of charge in most health facilities offering ART services, patients are still required to pay some user fees at health facility e.g. opening of folders, certain laboratory investigations and treatment of opportunistic infections. In addition there are some indirect costs these patients bear e.g. cost of transportation to the health care facility. Non-payment of services at every HAART clinics should be enforced and providing free treatment for opportunistic infections will also go a long way in improving adherence.
Certain limitations of this study should be recognized. The cross-sectional nature of the survey did not allow for inferences to be drawn as to causal relationship among variables. The use of self report medication adherence to assess medication adherence was a limitation in this study since participants had to recall their medication adherence in the previous week. Concerted efforts were made to reduce recall bias by limiting recall of medication to 7 days prior to the study which was in itself a limitation because of the possibility that subjects would either over- or underestimated their adherence to HAART. This was further worsened by the inability to corroborate patient self- report of adherence with viral loads and CD4 responses because of financial and logistic constraints of frequent laboratory monitoring. This was because restricted access to patient’s folders.
This study showed that medication adherence rate was low among PLHIV accessing treatment in UCTH Calabar, Nigeria. It is also obvious that there are barriers to adherence therefore efforts should be targeted and assessed for each patient so that appropriate adherence enhancing interventions can be undertaken. The authors therefore recommend that non-payment of services at every ART clinics and provision of free treatment should also include opportunistic infections and required investigations. This will go a long way in improving adherence. Also the focus during counselling sessions should discourage the use of traditional herbal remedies alongside HAART which has been seen to affect adherence in the present study. In addition, curtailing the activities of Alternative medical practitioners in the country claiming to have found a cure for HIV/AIDS would be of immense help. Pharmaceutical companies involved in manufacture of ARVs should ensure that all recommended ARV regimens should consist of not more than two pills per day.
Acquired immune deficiency syndrome
Highly active antiretroviral drugs
Human Immunodeficiency virus
President’s Emergency plan for AIDS Relief
Prevention of Maternal to Child transmission
People living with HIV/AIDS
University of Calabar Teaching Hospital
United States Agency for International Development.
UNAIDS: 2008 Report on the global. HIV/AIDS epidemic 2008. 2008, Geneva Switzerland
Federal Ministry of Health(FMOH): 2010 National HIV sero- prevalence Senntinnel Survey. 2010, Abuja: Federal Ministry of Health
Rao D, Kekwaletswe TC, Hosek S, Martinez J, Rodriguez F: Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care. 2007, 19 (1): 28-33. 10.1080/09540120600652303.
Lewis MP, Colbert A, Erlen J, Meyers M: A Qualitative study of persons who are 100% adherent to antiretroviral therapy. AIDS Care. 2006, 18 (2): 140-148. 10.1080/09540120500161835.
Moatti JP, Spire B: Economic and socio-behavioral issues related to highly active antiretroviral therapies for HIV infection: the contribution of social science research. Med Sci. 2003, 19 (8): 878-884.
Tapper M, Flexner C, Eron JJ, Molina J: Simplifying antiretroviral therapy. AIDS Care. 2004, 14 (7): 355-367.
National Agency for the control of AIDS (NACA): Antiretroviral therapy(ART) in Nigeria. Fact sheet 2011. 2011,
McPherson-Baker S, Jones D, Duran R, Klimas N, Schneiderman N: Development and implementation of a medication adherence training instrument for persons living with HIV (The MATI). Behav Modif. 2005, 29 (2): 286-317. 10.1177/0145445504272604.
Amico KR, Toro-Alfonso J, Fisher JD: An empirical test of the Information, Motivation and Behavioural Skills model of antiretroviral therapy adherence. AIDS Care. 2005, 17 (6): 661-673. 10.1080/09540120500038058.
Remien RH, Bastos FI, Terto Jnr V, Raxach JC, Pinto RM, Parker RG, et al: Adherence to antiretroviral therapy in a context of universal access, in Rio de Janeiro, Brazil. AIDS Care. 2007, 19 (6): 740-748. 10.1080/09540120600842516.
Weiser S, Wolfe W, Bangsberg D: Barriers to Antiretroviral Adherence to patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003, 34 (3): 281-288. 10.1097/00126334-200311010-00004.
Weiss L, French T, Finkelstein R, Waters M, Mukherjee RBA: HIV-related knowledge and adherence to HAART. AIDS Care. 2003, 15 (5): 673-679. 10.1080/09540120310001595159.
Paterson G, Swindells S, Mohr J: Adherence to protease inhibitor therapy and outcome in patients with HIV infection. Ann Intern Med. 2000, 133: 21-30.
Nilsson-Schönnesson L, Diamond PM, Ross MW, Williams M, Bratt G: Baseline predictors of three types of antiretroviral therapy (ART) adherence A 2-year follow-up. AIDS Care. 2006, 18 (3): 246-253.
Poppa A, Davidson D, Deutsch J, Dan G, Fisher M, Head S: British HIV Association (BHIVA)/British Association for sexual health and HIV (N‘BASHH) guidelines on provision of adherence support to individuals receiving antiretroviral therapy. HIV Med. 2004, 5 (S): 46-60.
Reynolds NR, Testa M, Marc L, Chesney M, Neidig J, Smith S, et al: Factors influencing medication adherence beliefs and self-efficacy in persons naïve to antiretroviral therapy: A multicentre, cross-sectional study. AIDS Behaviour. 2004, 8 (2): 141-150.
Mohammed MD: R. S. Adherence to antiretroviral drugs in North-Central zone of Nigeria. East Cent Afr J Pharm Sci. 2004, 7 (3): 52-55.
Iliyasu I, Kabir M, Abubakar I, Babashani M, Zubair Z: Compliance to antiretroviral therapy among AIDS patients in Amino Kano Teaching Hospital, Kano. Niger J Med. 2005, 14 (3): 290-294.
Monjok E, Smesny A, Okokon IB, Mgbere O, Essien J: Adherence to antiretroviral therapy in Nigeria: An overview of research studies and implications for policy and practice. HIV/AIDS - Res Palliat Care. 2010, 2: 69-76.
Svarstad B, Chewning B, Sleath B, Claessonc C: The brief medication questionnaire: A tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1998, 37: 113-124.
Olowookere SA, Fatiregun AA, Akinyemi JO, Bamgboye AEGKO: Prevalence and determinants of nonadherence to highly active antiretroviral therapy among people living with HIV/AIDS in Ibadan, Nigeria. J Infect Dev Ctries. 2008, 2 (5): 369-372.
Shaahu V, Lawoyin T, Sangowawa A: Adherence to Highly Active antiretroviral therapy(HAART) at a Federal Medical Center. Afr J Med Sci. 2008, 37: 29-36.
Agu KA, Okojie O, Oqua D, King RC, Omonaiye O, Onuoha C, et al: Medication Adherence and Risk factors for Non-adherence among Patients taking Highly Active Antiretroviral Therapy. West Afr J Pharm. 2011, 22 (1): 19-26.
Uzochukwu B, Onwujekwe O, Onoka A, Okoli C, Uguru N, Chukwuogo O: Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy Plan. 2009, 24: 189-196. 10.1093/heapol/czp006.
Falang KD, Akubaka N, Jimam NS: Patient Factors impacting Antiretroviral drug adherence in a Nigerian tertiary Hospital. J Pharmacol Pharmacother. 2012, 3 (2): 138-142.
Peltzer K: Preez NF-d, Ramlagan S, Anderson J: Antiretroviral treatment adherence among HIV patients in KwaZulu-Natal. South Afr BMC Public Health. 2010, 10: 1-10. 10.1186/1471-2458-10-1.
Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K: Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Publ Health. 2008, 8 (265): 1-10.
Talaam NC, Gatongi P, Rotich S: Factors Affecting Antiretroviral Drug Adherence among HIV/AIDS Adult Patients attending HIV/AIDS clinic at Moi Teaching and Refferal Hospital, Eldoret, Kenya. East Afr J Public Health. 2008, 5 (2): 74-78.
Wakibi SN, Ng’ang’a ZW, Mbugua GG: Factors associated with non-adherence to highly active antiretroviral therapy in Nairobi, Kenya. AIDS Res Ther. 2011, 43: 1-8.
Kacanek D, Jacobson D, Spiegelman D, Wancke C, Isac R, Wilson I: Incident depression symptoms are associated with poorer HAART adherence: A longitudinal analysis from the nutrition for Healthy living study (NFHL). J Acquir Immune Defic Syndr. 2010, 53 (2): 266-272. 10.1097/QAI.0b013e3181b720e7.
Kleeberger C, Phair J, Strathdee S, Detels R, Kingsley L, Jacobson L: Determinants of heterogenous adherence to HIV antiretroviral therapies in the Multicentre AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001, 26 (1): 82-92.
Gifford A, Bormann J, Shively M, Wright B, Richman D, Bozzette S: Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000, 23: 386-395.
Afolabi MO, Ijadunola KT, Fatusi AO, OA O: Determinants of adherence to antiretroviral drugs among people living with HIV/AIDS in the Ife-Ijesa of Osun State, Nigeria. Afr J Prim Health Care Fam Med. 2009, 1 (1): 6-
Bello SI: HIV Patients adherence to ART in Sobi Specialist Hospital, Illorin. Nigeria Glob J Med Res. 2011, 11 (2): 16-21.
Sow PG, Toure K, Coume M, Dia AT, Traore I: Predictors of ART adherence among HIV infected individuals in Dakar, Senegal. J Med Med Sci. 2012, 3 (4): 212-216.
Cauldbeck MB, O'Connor C, O'Connor MB, Saunders JA, Rao B, Mallesh VG, et al: Adherence to anti-retroviral therapy among HIV patients in Bangalore. India AIDS Res Ther. 2009, 6 (7): 1-8.
Malcolm S, Ng J, Rosen R, Stone V: An examination of HIV/AIDS patients who have excellent adherence to HAART. AIDS Care. 2003, 15 (2): 251-61. 10.1080/0954012031000068399.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/13/401/prepub
The authors would like to thank the staff of the President’s Emergency plan for Aids Relief (PEPFAR) clinic in the department of Family Medicine, University of Calabar Teaching Hospital for the support and assistance during the collection of data.
The authors declare that they have no competing interests.
OA conceived, designed and coordinated the study, she carried out statistical analysis and drafted the manuscript; OE contributed by means of her competence and experience in reviewing the manuscript critically for its intellectual content and also participated in the conception and design of the study. IO and OA participated in the design of the study, questionnaire and critically reviewed the manuscript. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Oku, A.O., Owoaje, E.T., Ige, O.K. et al. Prevalence and determinants of adherence to HAART amongst PLHIV in a tertiary health facility in south-south Nigeria. BMC Infect Dis 13, 401 (2013). https://doi.org/10.1186/1471-2334-13-401
- PLHIV, HAART
- Cross river